anti-CD16/anti-mesothelin/IL-15 trispecific immune-cell engager (University of Minnesota/GT Biopharma)

N/A

Report date: 2025/01/26 18:10:01

Base Information

Drug Nameanti-CD16/anti-mesothelin/IL-15 trispecific immune-cell engager (University of Minnesota/GT Biopharma)
Drug Alias NameNSCLC-TriKEanti-CD16/anti-mesothelin/IL-15 trispecific NK-cell engager (University of Minnesota/GT Biopharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionMesothelin modulatorsLow affinity immunoglobulin gamma Fc region receptor III agonistsInterleukin-15 receptors agonists
TargetsInterleukin-15 receptorsMesothelinLow affinity immunoglobulin gamma Fc region receptor III
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMesothelioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Minnesota
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MinnesotaGt Biopharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungMesothelioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A